72 week data of the HIDIT-1 trial: A multicenter randomised study comparing peginterferon alpha-2a plus adefovir vs. peginterferon alpha-2a plus placebo vs. adefovir in chronic delta hepatitis
dc.contributor.author | Drebber, U. | |
dc.contributor.author | Manns, M. P. | |
dc.contributor.author | Bozkaya, H. | |
dc.contributor.author | Meyer, S. | |
dc.contributor.author | Dienes, H. P. | |
dc.contributor.author | Wedemeyer, H. | |
dc.contributor.author | Yurdaydin, C. | |
dc.contributor.author | Dalekos, G. | |
dc.contributor.author | Erhardt, A. | |
dc.contributor.author | Cakaloglu, Y. | |
dc.contributor.author | Degertekin, H. | |
dc.contributor.author | Gurel, S. | |
dc.contributor.author | Zeuzem, S. | |
dc.contributor.author | Bock, T. | |
dc.contributor.author | Zachou, K. | |
dc.date.accessioned | 2021-03-04T13:06:15Z | |
dc.date.available | 2021-03-04T13:06:15Z | |
dc.identifier.citation | Wedemeyer H., Yurdaydin C., Dalekos G., Erhardt A., Cakaloglu Y., Degertekin H., Gurel S., Zeuzem S., Bock T., Zachou K., et al., "72 week data of the HIDIT-1 trial: A multicenter randomised study comparing peginterferon alpha-2a plus adefovir vs. peginterferon alpha-2a plus placebo vs. adefovir in chronic delta hepatitis", 42th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Barcelona, İspanya, 11 - 15 Nisan 2007, cilt.46 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.other | av_7a9d34f9-61b3-48bb-b9df-241a31214087 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/84000 | |
dc.identifier.uri | https://doi.org/10.1016/s0168-8278(07)61602-x | |
dc.language.iso | eng | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | İç Hastalıkları | |
dc.subject | Gastroenteroloji-(Hepatoloji) | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Tıp | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Klinik Tıp | |
dc.subject | GASTROENTEROLOJİ VE HEPATOLOJİ | |
dc.title | 72 week data of the HIDIT-1 trial: A multicenter randomised study comparing peginterferon alpha-2a plus adefovir vs. peginterferon alpha-2a plus placebo vs. adefovir in chronic delta hepatitis | |
dc.type | Bildiri | |
dc.contributor.department | , , | |
dc.identifier.volume | 46 | |
dc.contributor.firstauthorID | 133652 |
Bu öğenin dosyaları:
Dosyalar | Boyut | Biçim | Göster |
---|---|---|---|
Bu öğe ile ilişkili dosya yok. |
Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.
-
Bildiri [64839]